A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
58.3%) patients deceased and 2 (16.7%) were alive without evidence of cancer. Conclusion* in our series, bevacizumab had the expected outcomes and safety profile. Nevertheless, multicentric studies are needed to evaluate the true added value of bevacizumab to P-CT in ACC treatment in real-world practice and to identify predictive factors.doi:10.1136/ijgc-2021-esgo.45 fatcat:hoj7tckiyndqtkhxlvvznkcqyy